Leerink Swann initiated coverage on shares of PRA Health Sciences (NASDAQ:PRAH) in a research note published on Tuesday morning, The Fly reports. The brokerage issued a market perform rating and a $105.00 price target on the medical research company’s stock.
Other research analysts also recently issued research reports about the stock. Wolfe Research began coverage on shares of PRA Health Sciences in a research report on Tuesday, April 2nd. They set a market perform rating on the stock. SunTrust Banks boosted their target price on shares of PRA Health Sciences to $120.00 and gave the company an average rating in a research report on Monday, March 4th. BidaskClub upgraded shares of PRA Health Sciences from a hold rating to a buy rating in a research report on Friday, March 22nd. ValuEngine downgraded shares of PRA Health Sciences from a buy rating to a hold rating in a research report on Saturday, April 13th. Finally, Mizuho set a $100.00 target price on shares of PRA Health Sciences and gave the company a hold rating in a research report on Friday, May 3rd. Eight research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $113.22.
NASDAQ:PRAH opened at $98.23 on Tuesday. The company has a fifty day moving average price of $93.04. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.90 and a current ratio of 0.90. PRA Health Sciences has a 52 week low of $82.12 and a 52 week high of $121.98. The company has a market cap of $6.45 billion, a price-to-earnings ratio of 24.99, a P/E/G ratio of 1.33 and a beta of 1.12.
PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings data on Wednesday, May 1st. The medical research company reported $1.10 EPS for the quarter, beating the Zacks’ consensus estimate of $0.95 by $0.15. PRA Health Sciences had a net margin of 5.50% and a return on equity of 26.87%. The company had revenue of $722.00 million for the quarter, compared to analyst estimates of $730.84 million. During the same period in the prior year, the firm posted $0.85 EPS. The company’s quarterly revenue was up 2.9% on a year-over-year basis. As a group, equities analysts expect that PRA Health Sciences will post 4.63 EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in the stock. Motco raised its holdings in PRA Health Sciences by 937.0% during the first quarter. Motco now owns 280 shares of the medical research company’s stock worth $31,000 after buying an additional 253 shares during the last quarter. Financial Gravity Wealth Inc. acquired a new position in PRA Health Sciences during the first quarter worth $53,000. Manchester Capital Management LLC acquired a new position in PRA Health Sciences during the first quarter worth $57,000. CENTRAL TRUST Co raised its holdings in PRA Health Sciences by 28.2% during the first quarter. CENTRAL TRUST Co now owns 842 shares of the medical research company’s stock worth $93,000 after buying an additional 185 shares during the last quarter. Finally, Carroll Financial Associates Inc. raised its holdings in PRA Health Sciences by 7.6% during the first quarter. Carroll Financial Associates Inc. now owns 1,517 shares of the medical research company’s stock worth $167,000 after buying an additional 107 shares during the last quarter. Institutional investors own 99.42% of the company’s stock.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Recommended Story: What does EPS mean?
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.